| Database ID | Agent | Target | Cancer Type | Detail |
| DB00931 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | liver cancer | view |
| DB00932 | sorafenib and erlotinib | NA | bladder cancer | view |
| DB00933 | Cixutumumab ramucirumab | NA | prostate cancer | view |
| DB00934 | ramucirumab | Vascular endothelial growth factor receptor 2 | ovarian, primary peritoneal, or fallopian tube carcinoma | view |
| DB00935 | ramucirumab | Vascular endothelial growth factor receptor 2 | melanoma | view |
| DB00936 | ramucirumab | Vascular endothelial growth factor receptor 2 | colorectal cancer | view |
| DB00937 | ramucirumab | Vascular endothelial growth factor receptor 2 | renal cell carcinoma | view |
| DB00938 | ramucirumab | Vascular endothelial growth factor receptor 2 | liver cancer | view |
| DB00939 | cetuximab | Epidermal growth factor receptor | pancreatic cancer | view |
| DB00940 | bevacizumab erlotinib | NA | liver cancer | view |
| DB00941 | erlotinib | Epidermal growth factor receptor | liver cancer | view |
| DB00942 | aflibercept | Vascular endothelial growth factor receptor 2 | pancreatic cancer | view |
| DB00943 | bevacizumab erlotinib | NA | liver cancer | view |
| DB00944 | cetuximab | Epidermal growth factor receptor | pancreatic cancer | view |
| DB00945 | bevacizumab | Vascular endothelial growth factor | esophagusgastroesophageal junction cancer | view |